The Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) stock price soared 138% despite the lack of news from the clinical biopharma company specialising in Cellular IO. The lack of recent news releases from the company leaves us no choice but to examine its past releases.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The last significant release from Bellicum was in mid-March when the company halted its Phase 1/2 clinical trials due to serious adverse events in the patients dosed to focus on exploring its strategic options about the best path forward.
Top Broker Recommendation
- eToro Top stock trading platform with 0% commission – Read our Review
- Tickmill Regulated by the FCA – Read our Review
- Admirals (Admiral Markets) More than 4500 stocks & ETFs available – Read our Review
- Spreadex Spreadex has been around for a long time – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Since then, the company has not made any further announcements, which left its share price trading sideways near its all-time lows. However, the stock has been known to spike occasionally, as seen on the chart below, where it spiked higher in mid-April.
Today’s rally on Bellicum Pharma’s stock can be attributed to positive investor sentiment towards the company, as evidenced by the large number of shares that had changed hands at the time of writing; over 6.32 million shares had been bought and sold.
Bellicum halted the Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.
The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The company noted that the most recently treated patient experienced immune-mediated severe adverse events, including Grade 4 cytokine release syndrome (CRS).
Bellicum Pharma had to pause enrollment into the program since the Grade 4 cytokine release syndrome (CRS) is the second dose-limiting toxicity observed in the patient cohort from dose escalation.
The company acknowledged that it did not have the resources to optimise the clinical dose and schedule of BPX-601 cells and the activating agent rimiducid or the design of the BPX-601 cell construct to achieve a favourable risk/benefit profile.
The above reasons forced Bellicum Pharma to explore its strategic options, including actions related to clinical trials.
*This is not investment advice.
Bellicum Pharma (BLCM) stock price.
The Belicum Pharmaceuticals (BLCM) stock price soared 138.02% to trade at $0.9521, from Friday’s closing price of $0.4000.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.